000			01723 a2200493 4500
005			20250516150905.0
264		0	_c20140218
008			201402s 0 0 eng d
022			_a1532-3080
024	7		_a10.1016/j.breast.2013.04.011 _2doi
040			_aNLM _beng _cNLM
100	1		_aLu, Christine Y
245	0	0	_aTrastuzumab therapy in Australia: which patients with HER2+ metastatic breast cancer are assessed for cardiac function? _h[electronic resource]
260			_bBreast (Edinburgh, Scotland) _cAug 2013
300			_a482-7 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAnthracyclines _xadverse effects
650	0	4	_aAntibodies, Monoclonal, Humanized _xadverse effects
650	0	4	_aAntineoplastic Agents _xadverse effects
650	0	4	_aAustralia
650	0	4	_aBreast Neoplasms _xdrug therapy
650	0	4	_aCohort Studies
650	0	4	_aFemale
650	0	4	_aHeart Diseases _xchemically induced
650	0	4	_aHeart Function Tests _xstatistics & numerical data
650	0	4	_aHumans
650	0	4	_aLogistic Models
650	0	4	_aMiddle Aged
650	0	4	_aReceptor, ErbB-2 _xmetabolism
650	0	4	_aSocioeconomic Factors
650	0	4	_aTaxoids _xadverse effects
650	0	4	_aTrastuzumab
650	0	4	_aYoung Adult
700	1		_aSrasuebkul, Preeyaporn
700	1		_aDrew, Anna K
700	1		_aChen, Katie
700	1		_aWard, Robyn L
700	1		_aPearson, Sallie-Anne
773	0		_tBreast (Edinburgh, Scotland) _gvol. 22 _gno. 4 _gp. 482-7
856	4	0	_uhttps://doi.org/10.1016/j.breast.2013.04.011 _zAvailable from publisher's website
999			_c22741861 _d22741861